Department of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA; Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.
Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, University of Sydney, NSW, Australia.
Lancet Diabetes Endocrinol. 2018 Oct;6(10):809-820. doi: 10.1016/S2213-8587(18)30035-4. Epub 2018 Feb 20.
Cardiovascular disease remains the leading cause of mortality in patients with type 1 diabetes. Although cardiovascular disease complications are rare until adulthood, pathology and early markers can manifest in adolescence. Whereas advances have been made in the management of microvascular complications of type 1 diabetes, similar progress in reducing macrovascular complications has not been made. The reasons for the absence of progress remain incompletely understood, but most likely relate to the long time needed for cardiovascular disease to manifest clinically and hence for risk factor management to show a clinical benefit, thus allowing inertia to prevail for diagnosis and particularly for targeting risk factors. In this Review, we summarise paediatric data on traditional and novel risk factors of cardiovascular disease, provide an overview of data from previous and current clinical trials, discuss future directions in cardiovascular disease research for paediatric patients with type 1 diabetes, and advocate for the early identification and treatment of cardiovascular disease risk factors as recommended in multiple guidelines.
心血管疾病仍然是 1 型糖尿病患者的主要死亡原因。尽管心血管疾病并发症直到成年后才罕见发生,但病理和早期标志物可在青春期表现出来。虽然在 1 型糖尿病微血管并发症的管理方面取得了进展,但在减少大血管并发症方面尚未取得类似进展。进展缺失的原因尚不完全清楚,但很可能与心血管疾病在临床上表现出来以及危险因素管理显示出临床益处所需的时间较长有关,因此允许惯性在诊断方面占主导地位,特别是针对危险因素。在这篇综述中,我们总结了儿科心血管疾病传统和新型危险因素的数据,概述了以往和当前临床试验的数据,讨论了 1 型糖尿病儿科患者心血管疾病研究的未来方向,并提倡按照多项指南的建议,早期识别和治疗心血管疾病危险因素。